Literature DB >> 24870873

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24870873

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  3 in total

1.  Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.

Authors:  Maika Onishi; Solomon A Graf; Leona Holmberg; Sanaz Behnia; Andrei R Shustov; Karen Schiavo; Mary Philip; Edward N Libby; Ryan D Cassaday; John M Pagel; Jennifer E Roden; David G Maloney; Damian J Green; Brian G Till; Oliver W Press; Stephen D Smith; Ajay K Gopal
Journal:  Hematol Oncol       Date:  2014-09-18       Impact factor: 5.271

Review 2.  The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Authors:  Andrew M Evens; Lale Kostakoglu
Journal:  Blood       Date:  2014-11-27       Impact factor: 22.113

Review 3.  Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Authors:  Solomon A Graf; Ajay K Gopal
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.